HR negative

News alerts, weekly reports and conference planners

Entrez ID:

2099; 5241

Related biomarkers:

‹

›

HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	QL1209 (pertuzumab biosimilar) Sensitive: B - Late Trials QL1209 (pertuzumab biosimilar) Sensitive : B	QL1209 (pertuzumab biosimilar) Sensitive: B - Late Trials QL1209 (pertuzumab biosimilar) Sensitive : B
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria carboplatin + paclitaxel Sensitive : C2	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria carboplatin + paclitaxel Sensitive : C2
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	tegafur/uracil Sensitive: C3 – Early Trials tegafur / uracil Sensitive : C3	tegafur/uracil Sensitive: C3 – Early Trials tegafur / uracil Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	TCHP Sensitive: C3 – Early Trials TCHP Sensitive : C3	TCHP Sensitive: C3 – Early Trials TCHP Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	pertuzumab Sensitive: C3 – Early Trials pertuzumab Sensitive : C3	pertuzumab Sensitive: C3 – Early Trials pertuzumab Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: C3 – Early Trials pertuzumab + ado-trastuzumab emtansine Sensitive : C3	pertuzumab + ado-trastuzumab emtansine Sensitive: C3 – Early Trials pertuzumab + ado-trastuzumab emtansine Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	pembrolizumab + pertuzumab + trastuzumab-qyyp Sensitive: C3 – Early Trials pembrolizumab + pertuzumab + trastuzumab-qyyp Sensitive : C3	pembrolizumab + pertuzumab + trastuzumab-qyyp Sensitive: C3 – Early Trials pembrolizumab + pertuzumab + trastuzumab-qyyp Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: C3 – Early Trials trastuzumab + pyrotinib Sensitive : C3	trastuzumab + pyrotinib Sensitive: C3 – Early Trials trastuzumab + pyrotinib Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	durvalumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials durvalumab + fam-trastuzumab deruxtecan-nxki Sensitive : C3	durvalumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials durvalumab + fam-trastuzumab deruxtecan-nxki Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	cemiplimab-rwlc Sensitive: C3 – Early Trials cemiplimab-rwlc Sensitive : C3	cemiplimab-rwlc Sensitive: C3 – Early Trials cemiplimab-rwlc Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + TQB2303 (rituximab biosimilar) Sensitive: C3 – Early Trials trastuzumab + TQB2303 (rituximab biosimilar) Sensitive : C3	trastuzumab + TQB2303 (rituximab biosimilar) Sensitive: C3 – Early Trials trastuzumab + TQB2303 (rituximab biosimilar) Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	paclitaxel + doxorubicin hydrochloride Sensitive: C3 – Early Trials paclitaxel + doxorubicin hydrochloride Sensitive : C3	paclitaxel + doxorubicin hydrochloride Sensitive: C3 – Early Trials paclitaxel + doxorubicin hydrochloride Sensitive : C3
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C4 – Case Studies ado-trastuzumab emtansine Sensitive : C4	ado-trastuzumab emtansine Sensitive: C4 – Case Studies ado-trastuzumab emtansine Sensitive : C4
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	margetuximab Sensitive: C4 – Case Studies margetuximab Sensitive : C4	margetuximab Sensitive: C4 – Case Studies margetuximab Sensitive : C4
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	bevacizumab + disitamab vedotin Sensitive: C4 – Case Studies bevacizumab + disitamab vedotin Sensitive : C4	bevacizumab + disitamab vedotin Sensitive: C4 – Case Studies bevacizumab + disitamab vedotin Sensitive : C4
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	CDK19 inhibitor Sensitive: D – Preclinical CDK19 inhibitor Sensitive : D	CDK19 inhibitor Sensitive: D – Preclinical CDK19 inhibitor Sensitive : D
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	CDK8 inhibitor Sensitive: D – Preclinical CDK8 inhibitor Sensitive : D	CDK8 inhibitor Sensitive: D – Preclinical CDK8 inhibitor Sensitive : D
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D

HR negative

Associations